Fibroblastic reticular cell infection by hemorrhagic fever viruses.

abstract：:In the last 10 years, cancer stem cells have interested the scientific community because this small tumorigenic population is also associated with tumor progression in human patients and specific targeting of cancer stem cells could be a strategy to eradicate cancers currently resistant to conventional therapy. Clinic...

journal_title：Immunotherapy

authors： Iovino F,Meraviglia S,Spina M,Orlando V,Saladino V,Dieli F,Stassi G,Todaro M

更新日期：2011-01-01 00:00:00

abstract：:Evaluation of: Bostrom J, Shang-Fan Y, Kan D et al.: Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614 (2009). The longstanding held notion that one antibody equals one antigen and, hence, one function has been challenged in recent years. Improved t...

journal_title：Immunotherapy

authors： Valladares IG,Espinoza LR

更新日期：2009-09-01 00:00:00

abstract：:Epstein-Barr virus (EBV) infection is associated with a range of human malignancies of lymphocytic and epithelial cell origin. In addition to viral-mediated and genetic oncogenic events that lead to the establishment of EBV-associated malignancies, defects in the immune control of EBV likely play a significant role in...

journal_title：Immunotherapy

authors： Smith C,Khanna R

更新日期：2015-01-01 00:00:00

abstract：:Mycobacterium bovis bacille Calmette-Guerin (BCG) is one of the great success stories of immunotherapy as a treatment for superficial urothelial carcinoma of the bladder. Despite clinical effectiveness in over 50% of patients, the high incidence of local side effects and presence of nonresponders has led to efforts to...

journal_title：Immunotherapy

authors： Kresowik TP,Griffith TS

更新日期：2009-03-01 00:00:00

abstract：:Sarcoidosis is a systemic disease with an incidence of 1 to 40 per 100 000 persons per year. It predominantly affects people in the age of 20 to 40 years old. Disease course varies from mild self-limiting to chronic debilitating and life-threatening disease. Since the cause of sarcoidosis is unknown, curative therapy ...

journal_title：Immunotherapy

authors： Crommelin HA,Vorselaars AD,van Moorsel CH,Korenromp IH,Deneer VH,Grutters JC

更新日期：2014-01-01 00:00:00

abstract：:A 63-year-old female presented with cholestatic liver function tests in November 2016. Screening tests were negative for other causes and liver biopsy revealed primary biliary cholangitis (PBC) with autoimmune hepatitis (AIH) overlap. Ursodeoxycholic acid and azathioprine was initiated. In September 2018 she was diagn...

journal_title：Immunotherapy

authors： Bhave P,Pham A,Gordon A,Moore M

更新日期：2020-05-01 00:00:00

abstract：:Over the last few years, extensive research has improved our understanding of tumor immunology and has enabled the development of novel treatments. The state of the art of immunotherapy in various types of malignancies was exhaustively discussed in the 'Immunotherapy Bridge' meeting, which was held in Naples on 4-5 De...

journal_title：Immunotherapy

authors： Ascierto PA,Garbe C

更新日期：2020-02-01 00:00:00

abstract：:Non-coding RNAs (ncRNAs) are an abundant component of the human transcriptome. Their biological role, however, remains incompletely understood. Nevertheless, ncRNAs are highly associated with cancer development and progression due to their ability to modulate gene expression, protein translation and growth pathways. I...

journal_title：Immunotherapy

authors： Shek D,Read SA,Akhuba L,Qiao L,Gao B,Nagrial A,Carlino MS,Ahlenstiel G

更新日期：2020-05-01 00:00:00

abstract：AIM:We developed a novel approach to efficiently deliver autologous tumor antigens to the cytoplasm of dendritic cells (DC) using yeast cell wall particles (YCWP). MATERIALS AND METHODS:Loading of YCWP, leakage of protein from loaded YCWP and cytoplasmic delivery of YCWP content was assessed using fluorescent-tagged e...

journal_title：Immunotherapy

authors： Hardin MO,Vreeland TJ,Clifton GT,Hale DF,Herbert GS,Greene JM,Jackson DO,Berry JE,Nichols P,Yin S,Yu X,Wagner TE,Peoples GE

更新日期：2018-04-01 00:00:00

abstract：AIM:It is becoming apparent that emphysema is partly driven by self-reactive T cells inducing inflammatory damage. Thus, T cells become targets for therapy similar to other autoimmune diseases. Costimulatory blockade therapy targets disease-specific T cells, rendering them ineffective by blocking a necessary costimulat...

journal_title：Immunotherapy

authors： Newton AH,Danahy DB,Chan MA,Benedict SH

更新日期：2015-01-01 00:00:00

abstract：:Increasing evidence indicates the importance of human natural killer (NK) cells in the immune response against certain viral infections. In the present article, we summarize information on NK cell responses against several viruses and on the nature of NK cell receptor-ligand interactions involved in these responses. R...

journal_title：Immunotherapy

authors： Marcenaro E,Carlomagno S,Pesce S,Della Chiesa M,Parolini S,Moretta A,Sivori S

更新日期：2011-09-01 00:00:00

abstract：AIM:A 1-year follow-up study comparing the safety and tolerability of the dosing schedules, satisfaction and effectiveness of a novel microcrystalline tyrosine-adsorbed mite (Dermatophagoides pteronyssinus)-allergoid subcutaneous immunotherapy (Acarovac Plus™) in 30 adult patients (18-65 years) with allergic rhinitis a...

journal_title：Immunotherapy

authors： Roger A,Depreux N,Jurgens Y,Serra AT,Heath MD,Garcia G,Skinner MA

更新日期：2016-10-01 00:00:00

abstract：:In recent years, there have been reports of immunotherapy inducing objective clinical responses in limited numbers of cancer patients. More frequently, however, clinical responses are not observed. Understanding the immunological mechanisms underlying successful immunotherapy are crucial if the field is to move forwar...

journal_title：Immunotherapy

authors： Hardwick N,Chain B

更新日期：2011-06-01 00:00:00

abstract：:Currently, limited data exist on the safety of pembrolizumab in patients with metastatic melanoma who have developed severe immune-related adverse events following treatment with ipilimumab. We report a 45-year-old male patient with BRAF-mutant metastatic melanoma who discontinued treatment with ipilimumab due to trea...

journal_title：Immunotherapy

authors： Aya F,Fernández-Martínez A,Gaba L,Victoria I,Tosca M,Carrera C,Prat A,Arance A

更新日期：2016-06-01 00:00:00

abstract：:Progressive multifocal leukoencephalopathy (PML) is a rare and severe complication of natalizumab therapy in patients with multiple sclerosis and it may be accompanied by immune reconstitution inflammatory syndrome (IRIS). Here, we describe a case of abnormally severe IRIS, which occurred 2 months after natalizumab-as...

journal_title：Immunotherapy

authors： Calvi A,De Riz M,Pietroboni AM,Ghezzi L,Maltese V,Arighi A,Fumagalli GG,Jacini F,Donelli C,Comi G,Galimberti D,Scarpini E

更新日期：2014-01-01 00:00:00

abstract：:Brain tumors present unique therapeutic challenges and they include glioblastoma (GBM) and metastases from cancers of other organs. Current treatment options are limited and include surgical resection, radiation therapy, laser interstitial thermal therapy and chemotherapy. Although much research has been done on the d...

journal_title：Immunotherapy

authors： Liu Y,Chongsathidkiet P,Crawford BM,Odion R,Dechant CA,Kemeny HR,Cui X,Maccarini PF,Lascola CD,Fecci PE,Vo-Dinh T

更新日期：2019-10-01 00:00:00

abstract：AIMS:In IgA nephropathy, circulating immune complexes containing IgA1 are deposited on the glomerular mesangium, causing mesangial cell proliferation and acceleration of extracellular matrix production. The suppressive effect of jacalin, a galactose-binding lectin, on IgA production in vitro was determined. MATERIALS ...

journal_title：Immunotherapy

authors： Miyamoto K,Chiba T,Shinohara N,Nagata Y,Asakawa N,Kato S,Mizutani N,Murata T,Nomura S,Horiuchi T

更新日期：2012-12-01 00:00:00

abstract：:Programmed cell death-1 protein (PD-1) is an immune checkpoint that has gained popularity in the treatment of several advanced cancers. Inhibiting this checkpoint is known to enhance immune response, but is also known to diminish immune tolerance and to increase autoimmune toxicity. We discuss a case of rapid onset fu...

journal_title：Immunotherapy

authors： Araújo M,Ligeiro D,Costa L,Marques F,Trindade H,Correia JM,Fonseca C

更新日期：2017-06-01 00:00:00

abstract：:Mesenchymal stem cells (MSCs) show considerable promise as a cellular immunotherapy for the treatment of a number of autoimmune and inflammatory disorders. However, the precise physiologically and therapeutically relevant mechanism(s) by which MSCs mediate immune modulation remains elusive. Dental pulp stem cells are ...

journal_title：Immunotherapy

authors： Laing AG,Riffo-Vasquez Y,Sharif-Paghaleh E,Lombardi G,Sharpe PT

更新日期：2018-03-01 00:00:00

abstract：:The human IgG2 monoclonal antibody tremelimumab is an immune checkpoint inhibitor that blocks cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). The therapeutic response of anti-CTLA-4 monoclonal antibodies possess unique kinetics, in that antitumor responses are often observed after initial short-term disease prog...

journal_title：Immunotherapy

authors： Shimomura A,Fujiwara Y,Kondo S,Kodaira M,Iwasa S,Kitano S,Tanabe Y,Tamura K,Yamamoto N

更新日期：2016-01-01 00:00:00

abstract：:Aim: To evaluate treatment results in advanced/metastatic melanoma patients treated with anti-PD-1 immunotherapy in routine practice in oncology centers in Poland. Methods: Multicenter retrospective analysis included 499 patients with unresectable/metastatic (stage IIIC-IV) melanoma treated with anti-PD-1 in first-lin...

journal_title：Immunotherapy

authors： Cybulska-Stopa B,Pacholczak-Madej R,Kamińska-Winciorek G,Ziętek M,Czarnecka AM,Piejko K,Galus Ł,Ziółkowska B,Kieszko S,Kempa-Kamińska N,Calik J,Rolski J,Sałek-Zań A,Gajewska-Wicher K,Drosik-Kwaśniewska A,Rogala P,Kubiatow

更新日期：2021-03-01 00:00:00

abstract：AIMS:A therapeutic vaccine based on monocyte-derived dendritic cells (MDDCs) has been shown to represent a promising strategy for the treatment of cancer and viral infections. Here, we characterized the MDDCs used as an immunogen in a clinical trial for an anti-HIV-1 therapeutic vaccine. PATIENTS & METHODS:Monocytes o...

journal_title：Immunotherapy

authors： da Silva LT,da Silva WC,de Almeida A,da Silva Reis D,Santillo BT,Rigato PO,da Silva Duarte AJ,Oshiro TM

更新日期：2018-08-01 00:00:00

abstract：:Evaluation of: Turksma AW, Bontkes HJ, Ruizendaal JJ et al. Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J. Transl. Med. 11, 152-165 (2013). Survivin has been identified to be an inhibitor of apoptosis and is highly expressed in many cancers. A number o...

journal_title：Immunotherapy

authors： Lee WT

更新日期：2013-11-01 00:00:00

abstract：:Background: Immunotherapy has revolutionized the treatment of cancer, but this has not come without a cost. Although immune checkpoint inhibitors are less toxic than conventional chemotherapy, they are associated with more frequent autoimmune side effects. Case presentation: We report a case of a patient with metastat...

journal_title：Immunotherapy

authors： Abushalha K,Abulaimoun S,Silberstein PT

更新日期：2020-06-01 00:00:00

abstract：:Histone deacetylase inhibitors possess a broad array of antitumor activities; however, their net impact on the evolving antitumor immune response is highly dependent on the inhibitors used and the histone deacetylases they target. Herein, we sequentially focus on each stage of the antitumor immune response - from dend...

journal_title：Immunotherapy

authors： McCaw TR,Randall TD,Forero A,Buchsbaum DJ

更新日期：2017-12-01 00:00:00

abstract：:Background: Severe pneumonia and acute respiratory distress syndrome (ARDS) due to COVID-19 is a challenge for nowadays medical practice. Although there is no clarity in the principal mechanism of lung damage and ARDS development, it has been suggested that one of the main reasons of this pathology is the hyperactivat...

journal_title：Immunotherapy

authors： Cala-García JD,Sierra-Bretón JD,Cavelier-Baiz JE,Faccini-Martínez ÁA,Pérez-Díaz CE

更新日期：2020-10-01 00:00:00

abstract：:Tumor immune evasion is one of the hallmarks of cancer, and expression of the B7 family of immune checkpoints (PD-L1, PD-L2, B7-H3, B7x and HHLA2) is one mechanism of immune evasion by tumors to suppress T-cell function. Antibodies blocking these interactions of B7-1/B7-2/CTLA-4 and PD-L1/PD-L2/PD-1 have had remarkabl...

journal_title：Immunotherapy

authors： Janakiram M,Pareek V,Cheng H,Narasimhulu DM,Zang X

更新日期：2016-06-01 00:00:00

abstract：:Tumor-associated macrophages (TAMs), representing most of the leukocyte population in solid tumors, demonstrate great phenotypic heterogeneity and diverse functional capabilities under the influence of the local tumor microenvironment. These anti-inflammatory and protumorigenic macrophages modulate the local microenvi...

journal_title：Immunotherapy

authors： Petty AJ,Yang Y

更新日期：2017-03-01 00:00:00

abstract：:John L Stanford speaks to Hannah Wilson, Assistant Commissioning Editor John L Stanford is Chief Scientific Officer at BioEos Ltd (Kent, UK). Dr Stanford began his career as a senior lecturer and then reader in microbiology at Middlesex Hospital Medical School (London, UK), then University College London Medical Schoo...

journal_title：Immunotherapy

authors： Stanford JL

更新日期：2013-05-01 00:00:00

abstract：:Aim: To evaluate the long-term efficacy of sublingual immunotherapy (SLIT) in treating mite-sensitized allergic rhinitis (AR). Materials & methods: 150 AR children were randomly divided into SLIT and pharmacotherapy (PT) groups, receiving a 3-year course of SLIT along with PT or PT only. Results: The symptom and medic...

journal_title：Immunotherapy

authors： Chen WB,Shen XF,Li Q,Zhou WC,Cheng L

更新日期：2020-08-01 00:00:00